Trial Profile

A phase 2 clinical study of PRAX-628 in photo-sensitive epilepsy patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vormatrigine (Primary)
Indications Partial epilepsies
Focus Proof of concept; Therapeutic Use
Acronyms Photoparoxsymal Response (PPR) study

Most Recent Events

26 Mar 2024 According to a Praxis Precision Medicines media release, company will host a call on Tuesday, March 26 at 8:00 am ET to discuss the study results.
26 Mar 2024 Results presented in a Praxis Precision Medicines Media Release.
08 Jan 2024 According to a Praxis Precision Medicines media release, preliminary analysis of the 15 mg cohort showed that this cohort exceeds the expectations in terms of drug activity. The full data set will be disclosed after completion of the ongoing 45 mg cohort and full analysis of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com